First Publication using our Quantum Blue® Infliximab Trough Level Assay

We are very pleased to announce the publication of the first article describing our Quantum Blue® Infliximab trough level assay.

The authors around Professor F. Magro claim that:

On the basis of this study, we may conclude that the point-of-care Quantum Blue is a reliable alternative to the time-consuming ELISAs, allowing the fast and accurate assessment of IFX levels, which in turn contributes towards a proactive and cost-effective therapeutic managing of IBD patients.”

Click here for more information on the Quantum Blue® Infliximab assay or get access to the article here.